LEADER 04281nam  2200637Ia 450 
001 9910814402103321
005 20240410164830.0
010   $a1-61942-345-6
035   $a(CKB)2550000001040735
035   $a(EBL)3017947
035   $a(SSID)ssj0000853337
035   $a(PQKBManifestationID)11444110
035   $a(PQKBTitleCode)TC0000853337
035   $a(PQKBWorkID)10867473
035   $a(PQKB)11663640
035   $a(MiAaPQ)EBC3017947
035   $a(Au-PeEL)EBL3017947
035   $a(CaPaEBR)ebr10654918
035   $a(OCoLC)828140625
035   $a(EXLCZ)992550000001040735
100   $a20120802d2012      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aInfliximab$b[electronic resource] $epharmacology, uses and limitations /$fAntonio D. Medrano Acevedo and Montserrat Fajardo Gaitan, editors
205   $a1st ed.
210   $aNew York $cNova Science Publishers$dc2012
215   $a1 online resource (204 p.)
225 0 $aImmunology and immune system disorders
300   $aDescription based upon print version of record.
311   $a1-61942-343-X 
320   $aIncludes bibliographical references and index.
327   $a""INFLIXIMAB  PHARMACOLOGY, USES  AND LIMITATIONS ""; ""INFLIXIMAB  PHARMACOLOGY, USES  AND LIMITATIONS ""; ""Contents ""; ""Preface ""; ""The Risk of Infection in Patients Treated with Infliximab ""; ""Abstract ""; ""1. Definition and Functions of  Tumour Necrosis Factor ""; ""2. Anti-TNF Mechanism of Action: Infliximab ""; ""3. Risk of Infections in the Use  of Infliximab: Evidence""; ""4. Risk of Infection from the Use of  Anti-TNF (Inflximab): Mechanisms Involved""; ""5. Other Risk Factors for Infection  in Patients Treated with Infliximab ""; ""6. Infections ""; ""Bacterial Infections""
327   $a""Listeria """"Tuberculosis ""; ""Virus ""; ""Fungal Infections ""; ""Histoplasmosis ""; ""Coccidioidomycosis ""; ""Cryptococcosis ""; ""Aspergillosis ""; ""Candidiasis""; ""Pneumocystosis ""; ""7. Special Situations""; ""Perisurgical Infections ""; ""Hepatitis B Virus Infection ""; ""Hepatitis C Virus Infection ""; ""HIV Infection ""; ""Vaccines ""; ""Conclusions ""; ""References ""; ""Infliximab in Inflammatory Bowel Disease  ""; ""Abstract ""; ""Pharmacology""; ""Uses ""; ""Inflammatory Crohna???s Disease ""; ""Fistulizing Crohna???s Disease ""; ""Ulcerative Colitis""; ""Mucosal Healing ""
327   $a""Pouchitis""""Extraintestinal Manifestations ""; ""Limitations ""; ""Predictors of Response to Infliximab ""; ""Infections ""; ""Malignancies and Lymphoma ""; ""Cutaneous, Neurological and Liver Manifestations ""; ""Congestive Heart Failure ""; ""Pregnancy ""; ""References ""; ""Infliximab: Up-to-Date on Indications and Warnings ""; ""Abstract ""; ""1. Introduction""; ""2. Pharmacology""; ""2.1. Structure and Mechanisms of Action""; ""2.2. Absorption ""; ""2.3. Distribution ""; ""2.4. Metabolism and Excretion ""; ""2.5. Dosage and Administration ""; ""2.6. Pharmacogenomics""
327   $a""D) Chronic Eczema """"E) Hidradenitis Susppurativa (HS) ""; ""3.3. Other Verified Uses ""; ""a) SAPHO Syndrome ""; ""b) Kawasaki Disease ""; ""c) Pulmonary Fibrosis ""; ""d) Cap Polyposis ""; ""e) Postresuscitation Myocardial Dysfunction ""; ""f) B-Chronic Lymphocytic Leukemia ""; ""g) Diabetic Macular Edema ""; ""4. Warnings and Limitations""; ""4.1. Serious Infections ""; ""4.2. Malignancies ""; ""4.3. Hepatitis B virus Reactivation ""; ""4.4. Hepatotoxicity ""; ""4.5. Patients with Heart Failure ""; ""4.6. Hematological and Vascular Events ""; ""4.7. Hypersensitivity ""
327   $a""4.8. Neurological Events ""
410  0$aImmunology and Immune System Disorders
606   $aAnti-inflammatory agents
606   $aInfliximab$xTherapeutic use
606   $aInfliximab
615  0$aAnti-inflammatory agents.
615  0$aInfliximab$xTherapeutic use.
615  0$aInfliximab.
676   $a615.7/94
701   $aFajardo Gaitan$b Montserrat$01633476
701   $aMedrano Acevedo$b Antonio D$01633477
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910814402103321
996   $aInfliximab$93973237
997   $aUNINA